Literature DB >> 32493712

The right to know: ethical implications of antibody testing for healthcare workers and overlooked societal implications.

Kunal Vakharia1.   

Abstract

After the initial surge in cases of coronavirus (COVID-19), the outbreak has been managed differently in different countries. In the USA, it has been managed in many different ways between states, cities and even counties. This disparity is slowly becoming more and more pronounced with the advent of antibody testing. Although many argue over the potential merits of antibody testing as an immunity passport to allow the economy to restart, there are other implications that stand at the heart of the bioethical debate that are often overlooked. Particularly with COVID-19, there are many uncertainties and the discourse alone of antibodies presumes misinformation that may outweigh the epidemiological benefits of antibody testing. Although this paper does not seek to eliminate antibody testing, it does highlight the need for appropriate counselling both on a personal level with each patient but on a more global level. This moral standard of appropriate education is key to allowing the continued autonomy needed during this pandemic. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  distributive justice; ethics

Year:  2020        PMID: 32493712     DOI: 10.1136/medethics-2020-106467

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  2 in total

1.  Immunity passports, fundamental rights and public health hazards: a reply to Brown et al.

Authors:  Iñigo de Miguel Beriain; Jon Rueda
Journal:  J Med Ethics       Date:  2020-09-09       Impact factor: 2.903

2.  Prevalence of COVID-19 antibodies in healthcare workers at the peak of the pandemic in Mumbai, India: A preliminary study.

Authors:  Tanu Singhal; Sweta Shah; Reshma Naik; Amreen Kazi; Pooja Thakkar
Journal:  Indian J Med Microbiol       Date:  2020 Jul-Dec       Impact factor: 0.985

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.